Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.46 |
| ▸ | MTOR | P42345 | 7/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.40 |
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913754 | 0.79 | PIK3CA (0.49) | PIK3CAMTORFGFR3KDR | |
| SCHEMBL380261 | 0.76 | AAK1 (0.45) | RORC | |
| SCHEMBL409921 | 0.75 | PIK3CA (0.74) | PIK3CAMTOR | |
| SCHEMBL11925833 | 0.74 | KDR (0.70) | FGFR3KDR | |
| SCHEMBL410050 | 0.71 | PIK3CD (0.43) | PIK3CAMTORFGFR3KDR | |
| SCHEMBL1699239 | 0.71 | ATR (0.46) | — | |
| SCHEMBL3188717 | 0.70 | KDR (0.47) | FGFR3KDR | |
| SCHEMBL28705728 | 0.70 | ATR (0.45) | RORC | |
| SCHEMBL29435550 | 0.69 | RXFP1 (0.46) | RORC | |
| SCHEMBL15223288 | 0.69 | ATR (0.44) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2408773-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 23/4885FGFR3 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.